Should we routinely check for hepatitis B and C in patients with lichen planus or cutaneous vasculitis?

Area of Science:

• Hepatology
• Dermatology
• Infectious Diseases

Background:

• Hepatitis B virus (HBV) and Hepatitis C virus (HCV) infections are significant global health concerns.
• Cutaneous manifestations can occur in patients with chronic viral hepatitis.
• The association between lichen planus, cutaneous vasculitis, and viral hepatitis requires further investigation.

Purpose of the Study:

• To determine the prevalence of HBs-Ag and anti-HCV antibodies in patients with lichen planus and cutaneous vasculitis.
• To compare these prevalences with those in a control group.
• To assess any potential correlation between these skin conditions and hepatitis virus infections.

Main Methods:

• A cross-sectional study was conducted involving 43 patients with lichen planus, 19 with cutaneous vasculitis, and 30 healthy controls.
• Blood samples were analyzed for the presence of HBs-Ag and anti-HCV antibodies.
• Statistical analysis was performed to compare prevalence rates between the groups.

Main Results:

• Prevalence of HBs-Ag in lichen planus patients was 27.9%, anti-HCV was 20.9%, and both was 7%.
• Prevalence of HBs-Ag in cutaneous vasculitis patients was 15.8%, anti-HCV was 36.8%, and both was 15.8%.
• In the control group, HBs-Ag prevalence was 26.7%, anti-HCV was 10%, and both was 3.3%. No statistically significant differences were observed between groups.

Conclusions:

• The study found no statistically significant association between the presence of HBs-Ag or anti-HCV antibodies and lichen planus or cutaneous vasculitis.
• Hepatitis B and C virus infections do not appear to be significant risk factors for these dermatological conditions based on this cohort.
• Further research with larger sample sizes may be warranted to definitively rule out subtle associations.